Item 1.01. Entry into a Material Definitive Agreement.
On January 17, 2023, Aadi Bioscience, Inc. (the "Company") entered into
Amendment No.1 (the "Amendment") to the Negotiated Purchase Order Terms and
Conditions for Clinical and Commercial Product (the "Agreement") with Fresenius
Kabi, LLC ("Fresenius Kabi"). Pursuant to the Amendment, among other things, the
term of the Agreement was extended until March 31, 2024 (or such later date as
may be agreed upon between the parties), and certain terms related to pricing
and the Company's obligation to purchase certain minimum quantities of Fyarro
from Fresenius Kabi were updated and revised.
The Amendment contains other customary terms applicable to the manufacture of
therapeutics in the biotechnology industry. The foregoing summary is not
complete and is qualified in its entirety by reference to the Amendment, which
will be filed as an exhibit in a subsequent periodic report of the Company to be
filed under the Securities Exchange Act of 1934, as amended.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses